Cartesian Therapeutics Has Entered Into A Private Investment In Public Equity Financing Of Approximately $130M

Pursuant to the terms of the securities purchase agreement, the Company is selling an aggregate of 3,563,247 shares of its common stock, and 2,937,903 shares of its Series B Non-Voting Convertible Preferred Stock, each at a purchase price of $20.00 per share. Each share of Series B Preferred Stock is convertible into one share of Common Stock, subject to Cartesian stockholder approval thereof and certain beneficial ownership limitations set by the purchasers of the Series B Preferred Stock.